RxDoctor Payments Data

Earl Stoddard, MD

MOHS-Micrographic Surgery · Chubbuck, IDNPI 1760400238

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 35.0% of the total. Reporting peaked in 2019 at $796 and has fallen 70.1% since, to $238 in 2025.

$3,141in general payments, 2019–2025

Across 153 payments — averaging $20.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Merz North America, Inc.$426
  • Johnson & Johnson$279
  • Galderma Laboratories, L.p.$191
  • Novartis$180
  • Regeneron Healthcare Solutions, Inc.$170
  • plus $795 from 18 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Speaking & faculty fees$1505%
  • Food & beverage$2,89992%
  • Education$923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$533,971
Medicare patients
494
Services billed
3,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Acitretin23$10,443
Fluorouracil51$5,887
Imiquimod67$2,796
Doxycycline Monohydrate26$408
Ketoconazole20$232
Clobetasol Propionate11$209
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen15$99

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Chubbuck

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →